Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: Combined IL-21 and Low-Dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model

Figure 2

Rate of tumor growth and long-term survival in tumor-bearing mice after hgp10025–33 vaccination and cytokine therapy. Cumulative analysis of tumor growth rates are depicted for all replicate mice from 3 separate experiments in which mice were irradiated only (A), irradiated and vaccinated (B), or irradiated, vaccinated and treated with IL-2 (C), IL-21 (D), or IL-21 + IL-2 (E). Both IL-21 and IL-21 + IL-2 therapy delayed tumor progression in >50% of treated mice until day 42 while tumors in control and IL-2 treated mice all progressed more rapidly. IL-21 + IL-2 treated mice had a significant survival advantage (46%) over IL-21 (p = 0.035), or IL-2 (p << 0.0001) treated mice; and IL-21 therapy alone (20% survival) was significantly better than the vaccine only (p = 0.03) (F).

Back to article page